NAV

LY3295668

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
LY3295668
DrugBank Accession Number
DB18019
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 489.95
Monoisotopic: 489.1743091
Chemical Formula
C24H26ClF2N5O2
Synonyms
  • 1-((3-chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1h-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-2-methyl-, (2r,4r)-,4-piperidinecarboxylic acid
  • 4-piperidinecarboxylic acid, 1-((3-chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1h-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-2-methyl-, (2r,4r)-
  • Aurora a kinase inhibitor ly3295668
External IDs
  • AK-01
  • LY-3295668
  • LY3295668
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
LY3295668 ErbumineNot AvailableNot AvailableNot applicable

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
1WX8O5XV4R
CAS number
1919888-06-4
InChI Key
YQQZZYYQTCPEAS-OYLFLEFRSA-N
InChI
InChI=1S/C24H26ClF2N5O2/c1-14-10-21(31-30-14)29-20-7-6-18(26)19(28-20)12-24(23(33)34)8-9-32(15(2)11-24)13-16-4-3-5-17(25)22(16)27/h3-7,10,15H,8-9,11-13H2,1-2H3,(H,33,34)(H2,28,29,30,31)/t15-,24+/m1/s1
IUPAC Name
(2R,4R)-1-[(3-chloro-2-fluorophenyl)methyl]-4-({3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl}methyl)-2-methylpiperidine-4-carboxylic acid
SMILES
C[C@@H]1C[C@@](CC2=NC(NC3=NNC(C)=C3)=CC=C2F)(CCN1CC1=CC=CC(Cl)=C1F)C(O)=O

References

General References
Not Available
ChemSpider
72380146
PDBe Ligand
EG7
PDB Entries
6c2r

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentNeuroblastoma (NB)1
1CompletedTreatmentMetastatic Breast Cancer1
1CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
1, 2Active Not RecruitingTreatmentAdvanced Lung Non-Squamous Non-Small Cell Carcinoma / Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) / Stage III Lung Cancer AJCC v8 / Stage IIIA Lung Cancer AJCC v8 / Stage IIIB Lung Cancer AJCC v8 / Stage IIIC Lung Cancer AJCC v8 / Stage IV Lung Cancer AJCC v8 / Stage IVA Lung Cancer AJCC v8 / Stage IVB Lung Cancer AJCC v81
1, 2CompletedTreatmentAdult Solid Tumor / Breast Neoplasms / Head and Neck Neoplasms / Metastatic Cancer / Neoplasm / Small Cell Lung Cancer (SCLC) / Triple-Negative Breast Neoplasm1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP2.51Chemaxon
pKa (Strongest Acidic)4.59Chemaxon
pKa (Strongest Basic)8.51Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area94.14 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity127.21 m3·mol-1Chemaxon
Polarizability49.3 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 07, 2023 15:39 / Updated at September 28, 2023 05:47